• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Live Link
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • News
    • Careers

Get started
Sign in
Close
Truveta experts: Antidepressant treatment duration trends

Truveta experts: Antidepressant treatment duration trends

by Truveta staff | Feb 18, 2026 | Research

In this Truveta experts analysis, Amy Sullivan, MS examines real-world antidepressant prescribing episodes using linked electronic health record (EHR) and closed claims data from more than 14.5 million individuals. The analysis characterizes the duration, recurrence,...
Real-world evidence on heart failure from GLP-1 and advanced CKD populations

Real-world evidence on heart failure from GLP-1 and advanced CKD populations

by Truveta staff | Feb 12, 2026 | Research

Two new peer-reviewed studies published in the Journal of Cardiac Failure showcase how clinicians and researchers at Baylor Scott & White Research Institute, working in collaboration with Baylor Scott & White Health and Stony Brook Medicine investigators, are...
Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

by Truveta Research | Feb 11, 2026 | Featured research, Research

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

Use of GLP-1 RAs following label expansion for patients with CVD and overweight or obesity

by Truveta Research | Feb 10, 2026 | Research

Authors: Duy Do, PhD⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MD ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT,...
Hematologic oncology at scale: From population insight to patient-level risk signals

Hematologic oncology at scale: From population insight to patient-level risk signals

by Truveta staff | Feb 5, 2026 | Research

Hematologic oncology is at an inflection point. Over the past decade, innovation in blood cancers has accelerated dramatically. Breakthroughs like CAR-T and next-generation immunotherapies have redefined what’s possible for patients with blood cancers, turning...
Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

Evaluating changes in lidocaine and opioid administration on the day of IUD insertion, 2018-2025

by Truveta Research | Feb 2, 2026 | Research

Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
« Older Entries
Next Entries »

Share this


Recent posts

  • New Lilly study compares tirzepatide and semaglutide in real-world obesity care
  • Intelligence without evidence: Why health AI must be grounded in outcomes
  • Extracting seizure frequency from clinical notes at scale using the Truveta Language Model

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Research

Resources

Blog

News

Careers

Privacy notice

Contact us

© Truveta 2026

Our website uses cookies to ensure you have the best experience.